Clinical Trial Update: A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis [Phase 3]

View source ↗

Summary

Phase 3 pragmatic trial evaluating optimized dosing of rifampicin and moxifloxacin for drug-susceptible pulmonary tuberculosis, with HIV co-infection considerat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Moxifloxacin (moxifloxacin)
• Rifampicin

Snippet

Sponsor: Stellah Mpagama | Conditions: Tuberculosis, Human Immunodeficiency Virus | Phase 3 | Status: UNKNOWN